Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M.

Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that uses artificial intelligence on genetic ...

Union Minister of State for Science and Technology (Independent Charge) Dr Jitendra Singh on Wednesday said that India has ...

India is taking a major step toward sustainable infrastructure by introducing bio-bitumen made from farm wasste for road ...

Intelligent Bio Solutions stock rises after announcing a manufacturing partnership targeting over 40% cost savings, major ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial ...